More Big-name Pharma Firms Join NCATS Therapeutic Repurposing Effort | GenomeWeb

NEW YORK (GenomeWeb News) – The National Center for Advancing Translational Sciences said today that five additional pharmaceutical companies have joined its new program to enable researchers to study new uses for chemical compounds that have been set aside by drug makers

The five new participants in the NCATS program are Abbott, Bristol-Myers Squibb, GlaxoSmithKline, Janssen Pharmaceutical Research and Development, and Sanofi.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.